2022 / 03

DOI: 10.47183/mes.2022.033

ORIGINAL RESEARCH

N protein based vaccine against SARS-CoV-2 produces a strong T cell immune response to N Protein of novel strains

Rabdano SO1, Mukhin VE2, Makarov VV2, Rudakov GO1, Ruzanova EA1, Arakelov SA1, Khaitov MR3,4, Yudin SM2, Kryuchko DS5, Berzin IA5, Evtushenko AE1, Trukhin VP1, Skvortsova VI5
About authors

1 Saint Petersburg Scientific Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations of the Federal Medical Biological Agency, Saint Petersburg, Russia

2 Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia

3 Institute of Immunology of the Federal Medical Biological Agency, Moscow, Russia

4 Pirogov Russian National Research Medical University, Moscow, Russia

5 Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Sevastyan O. Rabdano
Svobody, 52, 198320, Krasnoye Selo, Saint Petersburg; ur.onadbar@naytsaves

About paper

Author contribution: Rabdano SO — study design, data analysis, data interpretation, manuscript writing; Mukhin VE — bioinformatic analysis, experimental procedure, data acquisition, statistical analysis, manuscript writing; Makarov VV — study design, data interpretation, manuscript writing; Rudakov GO — data analysis, statistical analysis, data interpretation, graphics preparation, manuscript writing; Ruzanova EA, Arakelov SA, Khaitov MR, Yudin SM, Kryuchko DS, Berzin IA, Evtushenko AE — study design, manuscript editing; Truhin VP, Skvortsova VI — research idea, study concept, manuscript editing.

Compliance with ethical standards: the study was approved by the Ministry of Health of the Russian Federation (clinical trial approval № 388 of 19 July 2021), Ethics Committee of MH RF (protocol № 282 of 19 July 2021) and Independent Ethics Committee (IEC) of the research center (protocols № 163 of 15 July 2021 and № 164 of 20 July 2021); the study was conducted in accordance with the principles of the World Medical Association (WMA) Declaration of Helsinki (1964) and its latest update (2013), tripartite guideline for Good Clinical Practice approved by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (E6 (R2) of 09 November 2016) and current legislation of the EEU and RF. Two copies of the informed consent form (volunteer information sheet) were to be signed and dated by the subjects and the researcher by their own handwriting.

Received: 2022-09-12 Accepted: 2022-09-26 Published online: 2022-09-30
|
  1. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. JCM. 2020; 9 (4): 967.
  2. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy. 2021; 19 (7): 877–88.
  3. van Oosterhout C, Hall N, Ly H, Tyler KM. COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021; 12 (1): 507–8.
  4. WHO Coronavirus (COVID-19) Dashboard. [cited 2022 Sep 2]. Available from: https://covid19.who.int/
  5. Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, et al. The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. JACC: Basic to Translational Science. 2022; 7 (3): 294–308.
  6. Martínez-Salazar B, Holwerda M, Stüdle C, Piragyte I, Mercader N, Engelhardt B, et al. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Front Cell Dev Biol. 2022; 10: 824851.
  7. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. LongTerm Effects of COVID-19 on Health Care Workers 1-Year PostDischarge in Wuhan. Infect Dis Ther. 2022; 11 (1): 145–63.
  8. Yewdell JW. Antigenic drift: Understanding COVID-19. Immunity. 2021; 54 (12): 2681–7.
  9. Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Stapleford K, editor. PLoS Pathog. 2022; 18 (2): e1010260.
  10. Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021; 133(7–8): 271–83.
  11. Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine. 2022; 3 (6): 100651.
  12. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. IJMS. 2021; 23 (1): 29.
  13. Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2 mutations in MHC-Irestricted epitopes evade CD8 + T cell responses. Sci Immunol. 2021; 6 (57): eabg6461.
  14. de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. Science. 2021; 24 (11): 103353.
  15. Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell. 2022; 185 (16): 2936–51.e19.
  16. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Reports. 2021; 36 (11): 109708.
  17. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Reports Medicine. 2021; 2 (7): 100355.
  18. Jamshidi E, Asgary A, Shafiekhani P, Khajeamiri Y, Mohamed K, Esmaily H, et al. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines & Immunotherapeutics. 2022; 18 (5): 2037384.
  19. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. Dutch RE, editor. J Virol. 2020; 94 (13): e00647-20, /jvi/94/13/JVI.00647-20.atom.
  20. Thura M, Sng JXE, Ang KH, Li J, Gupta A, Hong JM, et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports. 2021; 41 (9): BSR20211491.
  21. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARSCoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181 (7): 1489–501.e15.
  22. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus. J Immunol. 2008; 181 (6): 4168–76.
  23. Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J. 2012; 9 (1): 322.
  24. LaMere MW, Moquin A, Lee FEH, Misra RS, Blair PJ, Haynes L, et al. Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance. J Virol. 2011; 85 (10): 5027–35.
  25. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016; 8: 277–90.
  26. Wraith DC, Vessey AE, Askonas BA. Purified Influenza Virus Nucleoprotein Protects Mice from Lethal Infection. Journal of General Virology. 1987; 68 (2): 433–40.
  27. Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. International Immunology. 2009; 21 (10): 1175–83.
  28. Lazo L, Valdes I, Guillén G, Hermida L, Gil L. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines. 2019; 18 (2): 161–73.
  29. Lazo L, Hermida L, Zulueta A, Sánchez J, López C, Silva R, et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007; 25 (6): 1064– 70.
  30. Brentville V, Vankemmelbeke M, Metheringham R, Symonds P, Cook K, Urbanowicz R, et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants [Internet]. Immunology. 2021 Jun [cited 2021 Jul 6]. Available from: http://biorxiv.org/ lookup/doi/10.1101/2021.06.18.448932
  31. Coronavirus3D [Internet]. [cited 2022 Sep 2]. Available from: https://coronavirus3d.org/
  32. Re3data.Org. GISAID [Internet]. [cited 2022 Sep 2]. Available from: https://www.re3data.org/repository/r3d100010126
  33. Virus Pathogen Database and Analysis Resource (ViPR) - Flaviviridae — VIGOR4 Genome Annotation [Internet]. [cited 2022 Sep 2]. Available from: https://www.viprbrc.org/brc/ vigorAnnotator.spg?method=ShowCleanInputPage&decorator=flavi
  34. UGENE [Internet]. [cited 2022 Sep 2]. Available from: https://ugene.net/
  35. MUSCLE [Internet]. [cited 2022 Sep 2]. Available from: https:// www.drive5.com/muscle
  36. Titov A, Shaykhutdinova R, Shcherbakova OV, Serdyuk YV, Sheetikov SA, Zornikova KV, et al. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight. 2022; 7 (9): e157699.
  37. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374 (6572): abm0829.
  38. Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021; 384 (23): 2259–61.